Open AccessThe EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
Author(s) -
Kerolos Wagdy
Publication year - 2020
Publication title -
global cardiology science and practice
Language(s) - English
Resource type - Journals
ISSN - 2305-7823
DOI - 10.21542/gcsp.2020.31
Subject(s) - medicine , renal glucose reabsorption , reabsorption , diabetes mellitus , heart failure , type 2 diabetes , pharmacology , endocrinology , kidney
[no abstract - showing first paragraph]Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a relatively new class of antihyperglycemic medication that are well established for the management of type-2 diabetes mellitus (DM). They have a unique mechanism of action that targets the kidneys through inhibition of 90% of glucose reabsorption.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom